Fewer Hand-Offs for Shorter Timelines and Reduced Costs

Imagine the convenience of having a single point of contact guiding you through each step of drug development, from preclinical to early phase clinical studies. When you partner with Altasciences, our program managers work closely with you from the get-go to understand your unique needs and objectives, and deliver tailored solutions that meet your requirements.

Our streamlined approach and efficient coordination ensure seamless integration of activities, optimizing resources and maximizing productivity.

Explore our fact sheet to discover the power of centralized program management with Altasciences.
   
DOWNLOAD THE FACT SHEET

Ready to get started? Schedule a conversation with one of our experts. 
 

Taking full advantage of Canada's favorable regulatory landscape, Altasciences’ clinical facility in Montréal continues to be a popular choice, successfully completing hundreds of clinical trials each year.

In this issue of The Altascientist, we discuss the distinct benefits of conducting early phase clinical research on novel compounds in Canada versus other countries.  

 
DOWNLOAD NOW 

We cover:
•    Canadian CTA trials–time and cost savings
•    regulatory review process predictability
•    business efficiency cost savings
•    clinical trial participants
•    Canadian CTA frequently asked questions
 

You may also be interested in the following resources: 

Webpage: Altasciences' Three Clinical Trial Facilities

Videos:

• Accelerate Your Data With Altasciences’ Co-located Clinic and Lab
• Canada’s Regulatory Requirements for CTA Filings

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programmes, to offer an integrated/synchronised approach to CRO and CDMO services.

Enhance Your Outcomes With Our Analytical Services

Altasciences’ in-house R&D and formulation laboratories offer an extensive array of analytical solutions to support sponsors’ drug development and manufacturing programs.

Our services include:

•    HPLC/UPLC testing
•    Method development and validation
•    ICH stability storage and testing
•    APIs, excipients, and packaging components
•    Drug product release testing, including controlled substances

Take a virtual tour of our laboratories, or consult with one of our experts to discuss your study needs.
 

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

Altasciences’ North American Nonclinical Research Facilities

Our nonclinical research facilities include 585,000 square feet of purpose-built space in four strategically placed locations throughout North America. We provide comprehensive regulatory safety testing, bioanalysis, and other research support services for rodent and non-rodent species. Altasciences conducts over 700 safety studies annually, offering a full range of in vivo GLP and non-GLP safety assessments. Our solutions include pivotal toxicology, safety pharmacology, and laboratory services that meet global regulatory requirements for small and large molecules to support your IND, CTA, NDA, or BLA submissions.

Learn more about our specific capabilities at each of our facilities or consult with one of our experts to discuss your study needs.
 
EXPLORE OUR FACILITIES

Have five minutes? Discover our extensive site capabilities:

•    Webpage: Full Range of Preclinical Drug Development Solutions
•    Fact Sheet: Preclinical Services Capabilities
•    The Altascientist: Planning Your Preclinical Assessment

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.